The massive robot-making, pacemaker-inventing medtech company Medtronic is facing a financial snag: the humble stapler.
The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...
CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by ...
Andrew Chung, MD, performed the first biportal endoscopic spinal fusion with Medtronic's Mazor robot, according to a Feb. 17 news release.